chevron_leftBack
As of 14 June 2026, Adicet Bio, Inc. has a market cap of $82.02M USD, ranking #26951 globally and #4095 in the United States.
It ranks #2417 in the Healthcare sector, and #873 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$82.02MUSD
Enterprise Value
-$63.6MUSD
EBITDA (TTM)
-$115.73MUSD
Net Income (TTM)
-$116.8MUSD
PB Ratio
0.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Chen Schor
open_in_new
Employees
102
Founded
1947
Website
adicetbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.5% | -8.2% | 18% | -9.7% | -44% | -23% |
News
Loading...
ACET Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ACET
ISIN: US0070022076
Shares Out.:
Shares Outstanding:
9.348M1
Shares Float:
8.204M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
7.63 USD | |
|
0HX7
ISIN: US0070022076
|
7.34 USD | |
|
1IJA
Adicet Bio Inc Ordinary Shares
ISIN: US0070021086
|
0.3780 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
929K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
667K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
440K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
334K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
182K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
143K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
392K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
352K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
335K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
222K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
134K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
132K%
80.96B GBP
|
14.6
|
chevron_leftBack